GENinCode (LON:GENI) Trading Down 5.3% – Here’s Why

GENinCode Plc (LON:GENI)’s stock price fell 5.3% on Tuesday . The company traded as low as GBX 0.85 and last traded at GBX 0.90. 11,692,215 shares were traded during trading, an increase of 84% from the average session volume of 6,365,636 shares. The stock had previously closed at GBX 0.95.

GENinCode Stock Performance

The firm has a market capitalization of £6.53 million, a P/E ratio of -0.38 and a beta of 0.59. The company has a current ratio of 0.93, a quick ratio of 15.89 and a debt-to-equity ratio of 117.74. The business’s 50 day simple moving average is GBX 1.12 and its two-hundred day simple moving average is GBX 1.50.

GENinCode (LON:GENI) last released its quarterly earnings data on Monday, June 8th. The company reported GBX (2.08) earnings per share for the quarter. The firm had revenue of GBX 308 million for the quarter. GENinCode had a negative net margin of 185.47% and a negative return on equity of 409.40%. Sell-side analysts anticipate that GENinCode Plc will post -7.1299999 EPS for the current fiscal year.

About GENinCode

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.